Review
doi: 10.1038/nm0703-861.Immunopathogenesis and immunotherapy in AIDS virus infections
Affiliations
- PMID:12835706
- DOI: 10.1038/nm0703-861
Item in Clipboard
Review
Immunopathogenesis and immunotherapy in AIDS virus infections
Norman L Letvin et al. Nat Med.2003 Jul.
Display options
Format
Display options
Format
Abstract
The heterogeneity of HIV and the different human leukocyte antigen (HLA) backgrounds of infected individuals have posed challenges to understanding the pathogenesis of HIV infection. But continuing advances in our knowledge of the role of immune responses in controlling HIV viremia should help to define goals for immune-based therapies and vaccine strategies against AIDS.
Similar articles
- Cytotoxic T-cell recognition of HIV proteins and peptides.Nixon DF, McMichael AJ.Nixon DF, et al.AIDS. 1991 Sep;5(9):1049-59.AIDS. 1991.PMID:1718319No abstract available.
- Progression of HIV to AIDS: a protective role for HLA-B27?den Uyl D, van der Horst-Bruinsma IE, van Agtmael M.den Uyl D, et al.AIDS Rev. 2004 Apr-Jun;6(2):89-96.AIDS Rev. 2004.PMID:15332431Review.
- The role of human leukocyte antigen E and G in HIV infection.Tripathi P, Agrawal S.Tripathi P, et al.AIDS. 2007 Jul 11;21(11):1395-404. doi: 10.1097/QAD.0b013e32810c8bbc.AIDS. 2007.PMID:17589185Review.No abstract available.
- T lymphocyte responses in HIV-1 infection: implications for vaccine development.Brander C, Walker BD.Brander C, et al.Curr Opin Immunol. 1999 Aug;11(4):451-9. doi: 10.1016/S0952-7915(99)80076-4.Curr Opin Immunol. 1999.PMID:10448136Review.
- The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.Altfeld M, Allen TM, Kalife ET, Frahm N, Addo MM, Mothe BR, Rathod A, Reyor LL, Harlow J, Yu XG, Perkins B, Robinson LK, Sidney J, Alter G, Lichterfeld M, Sette A, Rosenberg ES, Goulder PJ, Brander C, Walker BD.Altfeld M, et al.J Virol. 2005 Apr;79(8):5000-5. doi: 10.1128/JVI.79.8.5000-5005.2005.J Virol. 2005.PMID:15795285Free PMC article.
Cited by
- Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope.Meissner EG, Duus KM, Gao F, Yu XF, Su L.Meissner EG, et al.Virology. 2004 Oct 10;328(1):74-88. doi: 10.1016/j.virol.2004.07.019.Virology. 2004.PMID:15380360Free PMC article.
- Phenotypic and functional profile of IFN-α-differentiated dendritic cells (IFN-DCs) from HIV-infected individuals.Santillo BT, Reis DDS, da Silva LT, Romani NT, Duarte AJDS, Oshiro TM.Santillo BT, et al.Hum Vaccin Immunother. 2019;15(9):2140-2149. doi: 10.1080/21645515.2018.1547603. Epub 2018 Dec 20.Hum Vaccin Immunother. 2019.PMID:30427745Free PMC article.
- Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection.Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgoz NO, Stone DR, Cohen DE, Johnston MN, Flynn T, Wurcel AG, Rosenberg ES, Altfeld M, Walker BD.Addo MM, et al.PLoS One. 2007 Mar 28;2(3):e321. doi: 10.1371/journal.pone.0000321.PLoS One. 2007.PMID:17389912Free PMC article.
- In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles.Kwon YJ, James E, Shastri N, Fréchet JM.Kwon YJ, et al.Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18264-8. doi: 10.1073/pnas.0509541102. Epub 2005 Dec 12.Proc Natl Acad Sci U S A. 2005.PMID:16344458Free PMC article.
- HIV cure strategies: which ones are appropriate for Africa?Abana CZ, Lamptey H, Bonney EY, Kyei GB.Abana CZ, et al.Cell Mol Life Sci. 2022 Jul 6;79(8):400. doi: 10.1007/s00018-022-04421-z.Cell Mol Life Sci. 2022.PMID:35794316Free PMC article.Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials